ACP-105

History

ACP-105 emerged from research into selective androgen receptor modulators designed to produce anabolic activity through androgen receptor signaling. Early development of SARMs focused on identifying orally active compounds capable of influencing skeletal muscle and bone while limiting some of the androgenic effects associated with traditional steroidal androgens. ACP-105 subsequently became a subject of pharmacological, metabolism, and anti-doping research. More recent studies have investigated its absorption, distribution, metabolism, and elimination characteristics, while analytical research has identified metabolites useful for detecting the compound in biological samples. ACP-105 has not progressed to an approved therapeutic medicine and remains an investigational compound.

NEXON

Chemical Structure

ACP-105 is a non-steroidal SARM and does not contain the classical four-ring steroid nucleus characteristic of testosterone and conventional anabolic-androgenic steroids.

Its molecular structure allows interaction with the androgen receptor and modulation of androgen-responsive cellular signaling.

NEXON

Pharmacology

ACP-105 acts through interaction with the androgen receptor (AR). As a SARM, its pharmacological development was based on the concept of producing androgen receptor–mediated anabolic activity with greater tissue selectivity than traditional androgenic steroids.

Available research places ACP-105 primarily within experimental pharmacology and anti-doping science rather than established clinical medicine.

NEXON

Mechanism of Action

The proposed mechanism involves androgen receptor activation.

The proposed mechanism involves androgen receptor activation.

• Oral absorption
• Systemic distribution
• Binding to androgen receptors
• Formation of receptor-ligand complexes
• Nuclear translocation
• Regulation of androgen-responsive gene transcription
• Modulation of muscle-cell differentiation pathways

NEXON

Pharmacodynamics

ACP-105 produces its biological activity primarily through androgen receptor signaling.

NEXON

Pharmacokinetics

ACP-105 is an orally active compound and undergoes gastrointestinal absorption followed by systemic distribution.

A 2025 ADME study provided an integrated computational profile of ACP-105 and predicted high gastrointestinal absorption, strong plasma-protein binding, and extensive hepatic metabolism. The study identified six predicted metabolites and indicated CYP3A4 as a major metabolic pathway. Importantly, these values are largely in-silico predictions, rather than established clinical pharmacokinetic measurements in humans.

NEXON

Physiological Effects

ACP-105 has been investigated primarily for its ability to modulate androgen receptor signaling and produce anabolic effects in androgen-responsive tissues. As a SARM, its proposed physiological activity includes effects on skeletal muscle and bone through androgen receptor–mediated regulation of cellular processes. These pathways may influence protein metabolism, maintenance of lean tissue, muscle physiology, and skeletal remodeling.

ACP-105 may also affect systemic endocrine function because androgen receptor modulation can influence the hypothalamic-pituitary-gonadal axis and endogenous androgen production. However, reliable human clinical data describing the magnitude and long-term consequences of these effects remain limited. Consequently, its physiological profile should be considered experimental rather than equivalent to that of an approved androgenic medicine.

Clinical Applications

ACP-105 has no established approved clinical application. Research into SARMs has broadly explored their potential for conditions involving loss of muscle mass, frailty, osteoporosis, and other androgen-responsive disorders, but ACP-105 itself has not demonstrated an established therapeutic indication through approved clinical development.

NEXON More recent work involving ACP-105 has focused heavily on pharmacokinetics, metabolism, toxicology, forensic analysis, and anti-doping detection rather than clinical treatment. The compound has been detected in doping-control investigations and remains an experimental substance.

NEXON

Safety Considerations

The use of anabolic-androgenic steroids may require consideration of cardiovascular, hematological, hepatic, endocrine, metabolic, and reproductive health.

Important safety considerations include:

• Cardiovascular health
• Blood pressure
• Hematological parameters
• Lipid profile
• Liver function
• Endocrine function
• Reproductive function
• Prostate health

The overall safety profile depends on the specific compound, formulation, concentration, duration of exposure, individual response, and patient characteristics. Appropriate medical evaluation and regular monitoring should be considered when clinically indicated.

NEXON

Potential Adverse Effects

Potential adverse effects associated with anabolic-androgenic steroid exposure may involve endocrine, cardiovascular, hematological, hepatic, dermatological, reproductive, and metabolic systems.

• Endocrine Effects
• Suppression of endogenous hormone production
• Alterations in hormonal balance
• Changes in reproductive hormone signaling
• Potential suppression of spermatogenesis

• Cardiovascular Effects
• Changes in lipid profile
• Possible increases in blood pressure
• Potential cardiovascular risk

• Hematological Effects
• Changes in hematocrit
• Changes in hemoglobin
• Possible increase in erythropoietic activity

• Dermatological Effects
• Acne
• Increased sebaceous activity
• Androgen-related hair loss in genetically predisposed individuals

• Reproductive Effects
• Changes in reproductive function
• Potential reduction in fertility
• Alterations in reproductive hormone regulation

• Hepatic & Metabolic Effects
• Changes in liver function parameters
• Alterations in metabolic markers
• Changes in glucose and lipid metabolism

The occurrence and severity of adverse effects vary according to the specific compound, formulation, exposure, duration of use, individual response, and patient characteristics.

NEXON

Contraindications

Condition Reason Severe hepatic disease Increased hepatic risk Hormone-sensitive cancers Androgen receptor sensitivity Pregnancy Potential risk of fetal development Known hypersensitivity Allergic reaction Significant cardiovascular disease Potential cardiovascular effects

NEXON

Drug Interactions

A comprehensive interaction profile may not be established for every anabolic-androgenic steroid or formulation.

• Potential interactions or clinical considerations may exist with:
• Anticoagulants
• Antidiabetic medications
• Hepatotoxic medications
• Other anabolic-androgenic steroids
• Other hormonal therapies
• Drugs affecting lipid metabolism

The clinical significance of potential interactions depends on the specific compound, formulation, dosage, duration of exposure, concomitant medications, and individual patient characteristics. Appropriate medical evaluation should be considered when multiple medications or hormonal therapies are used concurrently.

NEXON

Laboratory Monitoring

Laboratory Test Purpose CBC Monitor hematological parameters

ALT / AST Liver function

Bilirubin Hepatic assessment

Lipid Profile Cardiovascular risk assessment

Blood Pressure Cardiovascular monitoring

Total Testosterone Assess androgen status

LH / FSH Assess endocrine suppression

NEXON

Storage & Stability

• Store according to official product labeling.
• Protect from excessive heat and direct sunlight.
• Do not freeze.
• Maintain original packaging integrity.
• Keep away from children.
• Inspect packaging before use.

NEXON

Product Authenticity

Every genuine NEXON product should include appropriate quality verification features.

Authentication may include:

• Batch number tracking
• Manufacturing information
• Expiration date verification
• QR authentication system
• Authorized distribution verification

emphasizes transparency, traceability, and product quality control.

NEXON

Frequently Asked Questions

What is ACP-105? ACP-105 is an experimental non-steroidal selective androgen receptor modulator.

Is ACP-105 a steroid? No. ACP-105 is classified as a non-steroidal SARM.

Is ACP-105 oral or injectable? ACP-105 is an orally active compound.

Does ACP-105 aromatize? ACP-105 does not undergo conventional aromatization to estrogen.

What is ACP-105 mainly researched for? Research has focused on androgen receptor pharmacology, metabolism, toxicology, and anti-doping detection rather than an approved clinical indication.

Is ACP-105 approved for human use? No. ACP-105 has not been approved as a therapeutic medication. The FDA lists ACP-105 among SARM-related substances.

NEXON

Quality Commitment

is committed to maintaining high standards of manufacturing quality, product consistency, traceability, and scientific transparency.

Through quality control systems, authentication procedures, and responsible information sharing, NEXON aims to provide reliable pharmaceutical products and educational resources for healthcare professionals and informed users.

NEXON